Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Oct 9;97(9):1251–1259. doi: 10.1038/sj.bjc.6604018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Blood DC exhibit reduced immunostimulatory phenotype. (A) In a cohort of 40 patients with breast cancer (stage I, n=19; stage II, n=12 and stage IV, n=9), the level of expression of (A) CD86 and (B) HLA-DR was analysed according to the stage of disease and compared with controls (n=14). Shaded areas indicate normal reference ranges and box plots show means, standard deviations and ranges. (C and D) Antigen uptake of soluble (FITC-TT) and particulate (FITC-Dextran) antigens by blood DC from patients with early (stage II, n=7) and advanced (stage IV, n=4) disease compared to controls (n=7) is presented as the difference in mean fluorescence intensity. (E) Allo-stimulatory capacity of blood DC as tested by mixed leucocyte reaction (MLR). One representative experiment in which increasing numbers of blood DC purified from patients with early (stage II, n=2) or advanced (n=2) disease and a healthy control (n=1) were tested against allogeneic T cells purified from a panel (n=3) of healthy volunteers. The pairs giving maximal responses are shown as means of triplicate measurements. (F) Summary of proliferation data from MLRs using DC from patients with early (stage II, n=6) and advanced (stage IV, n=3) disease compared to controls (n=13) at a 1 : 30 DC:T ratio. Similar results were found for all DC:T ratios. (G) Summary of IFN-γ secretion in culture supernatants collected from MLRs at a 1 : 30 DC:T ratio as assessed by ELISA. Error bars correspond to s.e.m. Significant differences compared to controls are shown as ^*P<0.05, ^**P<0.01 and ^***P<0.001. All samples were analysed prior to therapy.